PROpel D081SC00001 - A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

September 27, 2019
https://clinicaltrials.gov/ct2/show/NCT03732820
Cancer - Prostate
Principal Investigator: Clara Hwang, MD

Metastatic Castration resistant Prostate

Olaparib

Abiraterone

Propel

Open